 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
294 News |  |
| «123» |
- || lenabasum (JBT-101) / Corbus Pharma, Kaken Pharma
Enrollment closed: JBT-101 in Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov) - Apr 5, 2021
P2, N=108, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting
- |||| lenabasum (JBT-101) / Corbus Pharma, Kaken Pharma
Trial completion: Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis (clinicaltrials.gov) - Mar 26, 2021
P2, N=425, Completed, Sponsor: Corbus Pharmaceuticals Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || lenabasum (JBT-101) / Corbus Pharma, Kaken Pharma
Trial completion date, Trial primary completion date: JBT-101 in Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov) - Mar 10, 2021
P2, N=100, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Trial completion date: Jun 2021 --> Sep 2021 | Trial primary completion date: Feb 2021 --> Aug 2021
- | acebilustat (CTX-4430) / Celtaxsys, lenabasum (JBT-101) / Corbus Pharma, Kaken Pharma
Journal: Cystic fibrosis - Ten promising therapeutic approaches in the current era of care. (Pubmed Central) - Mar 4, 2021
This has led to reinvigorated efforts and innovations in treatment approaches and care delivery. Numerous challenges remain because of genetic and phenotypic heterogeneity, access issues, and therapeutic costs, but the collaborative approach between stakeholders for continued innovation fuels optimism.
- lenabasum (JBT-101) / Corbus Pharma, Kaken Pharma
[VIRTUAL] Cannabis and Cannabinoid Use in Patients with Systemic Lupus Erythematosus () - Feb 21, 2021 - Abstract #CRAAHPA2021CRA-AHPA_153;
The proportion of SLE patients who regularly use cannabis may be significant. The cases reporting potential harm warrant further study.
- | lenabasum (JBT-101) / Corbus Pharma, Kaken Pharma
Journal: "Molecular Mechanisms for the Inflammation-Resolving Actions of Lenabasum". (Pubmed Central) - Feb 20, 2021
Two putative molecular mechanisms are suggested to better understand how lenabasum produces this action. In both different metabolites of arachidonic acid act as mediators.
- lenabasum (JBT-101) / Corbus Pharma, Kaken Pharma
[VIRTUAL] SPONTANEOUS CORONARY ARTERY DISSECTION IN A PATIENT WITH DERMATOMYOSITIS (eAbstract site) - Feb 17, 2021 - Abstract #ACC2021ACC_4892;
On our search we only found one reported case with polymyositis, and that woman was post-partum. It is underdiagnosed due to variability in presentation and on angiography.
- | lenabasum (JBT-101) / Corbus Pharma, Kaken Pharma
Trial completion date: JBT-101 in Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov) - Feb 9, 2021
P2, N=100, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
It is underdiagnosed due to variability in presentation and on angiography. Trial completion date: Dec 2020 --> Jun 2021
- || Orencia (abatacept) / BMS
Clinical, Journal: Clinical trials and novel therapeutics in Dermatomyositis. (Pubmed Central) - Feb 4, 2021
At the forefront of these are immunoglobulin, Lenabasum, and Abatacept for which phase III clinical trials are ongoing. In addition, promising clinical studies are ongoing or reported for KZR-616, anti-B cell therapy, anti-interferon drugs, and Repository Corticotrophin Injection (RCI).
- || lenabasum (JBT-101) / Corbus Pharma, Kaken Pharma
Clinical, P2 data, Journal: Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with systemic sclerosis. (Pubmed Central) - Dec 16, 2020
In addition, promising clinical studies are ongoing or reported for KZR-616, anti-B cell therapy, anti-interferon drugs, and Repository Corticotrophin Injection (RCI). Despite a short trial duration in a small number of patients, lenabasum improved efficacy outcomes and underlying disease pathology with a favorable safety profile in this Phase 2 study in dcSSc.
- || lenabasum (JBT-101) / Corbus Pharma, Kaken Pharma
Clinical, Journal: Lenabasum for skin disease in patients with diffuse cutaneous systemic sclerosis. (Pubmed Central) - Dec 1, 2020
report promising results of a small multicenter, double-blind, randomized, placebo-controlled, phase II study of lenabasum, a cannabinoid type 2 (CB2) receptor agonist, for the treatment of skin disease in patients with early diffuse cutaneous systemic sclerosis (dcSSc) on stable background immunosuppression. This study is important because it examines the effects of cannabinoid (CB) modulation in SSc, a hitherto unexplored pathway, it uses the American College of Rheumatology (ACR) Combined Response Index in Systemic Sclerosis (CRISS) index as an outcome in a 12-week as opposed to its intended use in 12-month clinical trials, and it redemonstrates the utility of obtaining skin biopsies to assess secondary outcomes in SSc clinical trials.
- ||||| lenabasum (JBT-101) / Corbus Pharma, Kaken Pharma
Clinical: #Scleroderma @sclerodermaUM @Worldsclerofnd @SclerodermaNews $CRBP While the Lenabasum trial was a failure, it did provide unknown incredible data for Cellcept, Mycophenelate. The Majority of patients were on Cellcept. Average MRSS was -10.1 and average Criss was .95. Incredible: (Twitter) - Nov 10, 2020
- lenabasum (JBT-101) / Corbus Pharma, Kaken Pharma
[VIRTUAL] CB2 Receptor Distribution and Effects of LenabasumTM in Dermatomyositis In Vitro (Feed 11) - Oct 8, 2020 - Abstract #ACRARHP2020ACR_ARHP_2731;
We found that CB2R expression differs between the skin and blood of DM patients, with higher expression occurring in skin. pDCs were found to be major expressors of CB2R in DM skin through IMC and FC, suggesting that these cells may be most affected by Lenabasum in DM.
- lenabasum (JBT-101) / Corbus Pharma, Kaken Pharma
[VIRTUAL] Preliminary Baseline Subject Demographics and Disease Characteristics in a Phase 3 Clinical Trial of the Safety and Efficacy of Lenabasum in Dermatomyositis (DETERMINE) () - Oct 8, 2020 - Abstract #ACRARHP2020ACR_ARHP_2337;
P2, P3
Baseline demographics of enrolled subjects are as expected (majority white, female, and middle-aged) and reflects the estimated proportion of classic to clinically amyopathic patients in the overall DM population (~5:1). Most subjects are concurrently receiving immunomodulatory drugs and have active, refractory disease with glucocorticoid use in half of subjects.
- lenabasum (JBT-101) / Corbus Pharma, Kaken Pharma
[VIRTUAL] Clinical Outcomes Among Participants with Diffuse Systemic Sclerosis Contracting COVID-19 During Clinical Studies of Lenabasum: A Case Series () - Oct 8, 2020 - Abstract #ACRARHP2020ACR_ARHP_2050;
P2, P3
This suggests the diffuse cutaneous SSc subjects in this cohort are not more vulnerable to COVID-19 infection than the general population. All 4 trial participants despite 2 with confirmed ILD had acceptable outcomes, in the context of continued or resumed lenabasum treatments.
- || Actemra IV (tocilizumab) / Roche, JW Pharma, cyclophosphamide intravenous / Generic mfg.
Review, Journal: Treatment of systemic sclerosis-associated interstitial lung disease (Pubmed Central) - Sep 13, 2020
All 4 trial participants despite 2 with confirmed ILD had acceptable outcomes, in the context of continued or resumed lenabasum treatments. Current drug studies may provide innovative therapeutic perspectives for SSc-ILD and could significantly improve the prognosis of affected patients in the future.
- | lenabasum (JBT-101) / Corbus Pharma, Kaken
Review, Journal: Eicosanoid mediation of cannabinoid actions. (Pubmed Central) - Sep 2, 2020
However, synthetic agents such as CP55,940, ajulemic acid, JWH-133 and WIN-55,212-2 were also investigated for interaction with eicosanoids...While not all cannabinoid activities can be accounted for, many are best explained by eicosanoid participation. The recent surge in interest in "medical marijuana" makes understanding mechanisms of cannabinoid actions particularly important.
- ||| lenabasum (JBT-101) / Corbus Pharma, Kaken Pharma
Trial completion date: RESOLVE-1: Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis (clinicaltrials.gov) - Aug 17, 2020
P3, N=365, Active, not recruiting, Sponsor: Corbus Pharmaceuticals Inc.
The recent surge in interest in "medical marijuana" makes understanding mechanisms of cannabinoid actions particularly important. Trial completion date: Mar 2020 --> May 2022
- |||| lenabasum (JBT-101) / Corbus Pharma, Kaken Pharma
Enrollment closed, Trial completion date, Trial primary completion date: DETERMINE: Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis (clinicaltrials.gov) - Aug 13, 2020
P3, N=176, Active, not recruiting, Sponsor: Corbus Pharmaceuticals Inc.
Trial completion date: Mar 2020 --> May 2022 Recruiting --> Active, not recruiting | Trial completion date: Dec 2021 --> Sep 2022 | Trial primary completion date: Dec 2021 --> Sep 2021
- |||||||| lenabasum (JBT-101) / Corbus Pharma, Kaken Pharma
New P2/3 trial: A research study to collect long term safety information from subjects who have received study treatment from a qualifying lenabasum Corbus trial. (EUDRACT) - Aug 11, 2020
P2/3, N=100, , Sponsor: Corbus Pharmaceuticals, Inc.
- |||| lenabasum (JBT-101) / Corbus Pharma, Kaken
Lenabasum (cannabinoid rcptr agonist) studied in Systemic Sclerosis - LEN (n=27) vs PBO (n=15). At wk 16 LEN had better responses by CRISS (skin) score (0.33, vs 0; P=0.07) w/ reduced gene expression for inflammation & fibrosis & improved skin histology https://t.co/oddSMvjnc9 (Twitter) - Jul 29, 2020
- ||| lenabasum (JBT-101) / Corbus Pharma, Kaken
And comparing Lenabasum with Tozi just shows ignorance of biology. Tozi blocks IL-6 receptor. Going without IL-6 is the last thing you want to do!! Do you know what increases IL-6 the most? Physical exercise. Also sauna. Blocking IL-6 you are blocking a needed stress response. (Twitter) - Jul 9, 2020
- || lenabasum (JBT-101) / Corbus Pharma, Kaken
And Lenabasum is going to innaugurate this new era. (Twitter) - Jul 9, 2020
- || lenabasum (JBT-101) / Corbus Pharma, Kaken
Not even getting into increased infection rates... And why is lenabasum special? Because it does not block the inflammatory response. Its still there. But it simply promotes, strongly, its natural resolution. All inflammatory diseases are in fact failures of resolution. (Twitter) - Jul 9, 2020
- |||| lenabasum (JBT-101) / Corbus Pharma, Kaken
Clinical: @sclerodermaUM @TheHunter5515 The Lenabasum study is a "prospective" study using ACR CRISS https://t.co/6tt6IstLk0 (Twitter) - Jul 6, 2020
- lenabasum (JBT-101) / Corbus Pharma, Kaken
[VIRTUAL] PROVISIONAL AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) COMBINED RESPONSE INDEX IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (CRISS) SCORE CORRELATES WITH CHANGES IN PATIENT-REPORTED OUTCOMES (PRO) () - Jul 5, 2020 - Abstract #SSWC2020SSWC_1266;
ACR CRISS score consistently correlated with changes in measures of how the patient feels and functions including those measures not captured in ACR CRISS score calculation, whereas δ mRSS did not. Based on these findings, ACR CRISS score may be a more relevant choice as a primary efficacy outcome than δ mRSS in improvement trials in SSc.
- lenabasum (JBT-101) / Corbus Pharma, Kaken
[VIRTUAL] Lenabasum clinical development update () - Jul 5, 2020 - Abstract #SSWC2020SSWC_1099;
- lenabasum (JBT-101) / Corbus Pharma, Kaken
[VIRTUAL] Major producers of IFNg and CB2 receptor distribution in dermatomyositis () - Jul 1, 2020 - Abstract #SID2020SID_724;
Increased CB2Rs in the skin could indicate increased action of Lenabasum in skin compared to blood. Increased CB2Rs on lymphocytes could indicate a preferential action of Lenabasum on lymphocytes compared to dendritic cells.
- lenabasum (JBT-101) / Corbus Pharma, Kaken
Patient demographics and baseline disease characteristics in a multicentre, randomised, double-blind, placebo-controlled phase 2b study of lenabasum, a selective cannabinoid receptor type 2 agonist, in cystic fibrosis () - Jun 29, 2020 - Abstract #ECFS2020ECFS_146;
Increased CB2Rs on lymphocytes could indicate a preferential action of Lenabasum on lymphocytes compared to dendritic cells. This is the first Phase 2b study to use rate of PEx as the primary efficacy outcome in a patient population with any CF mutation, bacterial profile, who maintained their current standard of care and who are at higher risk of PEx in the next 6 months.
- ||| lenabasum (JBT-101) / Corbus Pharma, Kaken
Lenabasum, an experimental cannabinoid receptor type 2 agonist, may benefit systemic sclerosis, said Dr Barbara White @CorbusPharma at #EULAR20 #EULAR2020 @eular_org https://t.co/YZnbceKXnw (Twitter) - Jun 11, 2020
- lenabasum (JBT-101) / Corbus Pharma, Kaken
[VIRTUAL] BASELINE EUROPEAN PATIENT DEMOGRAPHICS AND DISEASE CHARACTERISTICS IN A PHASE 3 STUDY OF SAFETY AND EFFICACY OF LENABASUM, A CB2 AGONIST, IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS () - May 22, 2020 - Abstract #EULAR2020EULAR_2831;
While the use of background immunosuppressive therapies is significant irrespective of geographic regions, MTX use is highest in the EU. Benefits of having inclusive eligibility criteria are that they facilitated timely full enrollment and will make the study more relevant to real-world practice.
- lenabasum (JBT-101) / Corbus Pharma, Kaken
[VIRTUAL] LENABASUM, A CB2 AGONIST, INHIBITS INFLAMMASOME ACTIVATION () - May 22, 2020 - Abstract #EULAR2020EULAR_1633;
Benefits of having inclusive eligibility criteria are that they facilitated timely full enrollment and will make the study more relevant to real-world practice. Lenabasum inhibits inflammasome activation, which could contribute to potential therapeutic efficacy in SSc and other autoimmune diseases.
- ||| lenabasum (JBT-101) / Corbus Pharma, Kaken
$CRBP @CorbusPharma @PublicServant87 @AHimar33 @rplenge @sclerodermaUM @TheHunter5515 @DrSamGirgis @DrMattMcCarthy @megtirrell @bret_jensen @zbiotech @MaxJacobsEdison @MaxKonigMD @ScottGottliebMD @sclerodermaUM Test Lenabasum (Twitter) - Apr 19, 2020
- || lenabasum (JBT-101) / Corbus Pharma, Kaken
$CRBP @CorbusPharma $ibb $XBB $MJ @rplenge @TheHunter5515 @DrNancyM_CDC @realwillmeade @jimcramer @Mykalt45 @PublicServant87 @redacre @TomSilver39 @ToddHarrisonDC @Pharmdca @VIPSheffTrades @sharkbiotech @InvestorsLive @lblegend33 @DrSamGirgis Move over for Lenabasum - Corbus (Twitter) - Apr 12, 2020
- |||| lenabasum (JBT-101) / Corbus Pharma, Kaken
$CRBP Corbus Lenabasum now @PublicServant87 @sharkbiotech @rplenge @smerconish @sclerodermaUM @bret_jensen @FranciscoMarty_ @VIPSheffTrades @InvestorsLive $xbi $mj $ibb @realDonaldTrump @AHimar33 @odibro https://t.co/3AJGfjpiob https://t.co/qG6Afe2FQd https://t.co/R8y5CXrUSm (Twitter) - Apr 10, 2020
- ||| lenabasum (JBT-101) / Corbus Pharma, Kaken
This is what Corbus's Lenabasum's MOA addresses w/o immuno suppression @odibro @DrMattMcCarthy @JohnCendpts @ldtimmerman @timseymour @RedDogT3 @jaybradner @microbephage @FranciscoMarty_ @NJHealth @cysticfibrosis @MerandaCF https://t.co/Bf4EECvAgG (Twitter) - Apr 9, 2020
- ||| lenabasum (JBT-101) / Corbus Pharma, Kaken
$CRBP This is what Corbus's Lenabasum's MOA addresses w/o immuno suppression $XBI $MJ @TomSilver39 @todd_harrison @ScottGottliebMD @florian_krammer @sclerodermaUM @FranciscoMarty_ @InvestorsLive @VIPSheffTrades $AMRN $VRTX @CFAware @lblegend33 $IBB https://t.co/eF8xc8yq74 (Twitter) - Apr 9, 2020
- |||| lenabasum (JBT-101) / Corbus Pharma, Kaken
$CRBP @AH33 @PublicServant87 @todd_harrison @InvestorsLive @sharkbiotech @TheHunter5515 @FranciscoMarty_ @jaybradner @BioBreakout @florian_krammer @JohnCendpts @odibro @lblegend33 @Opal_Chip @bs2537 Lenabasum works here to suppress Covid 19 cytokine storms w/o immuno suppression (Twitter) - Apr 9, 2020
- || lenabasum (JBT-101) / Corbus Pharma, Kaken Pharma
Trial completion date, Trial primary completion date: JBT-101 in Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov) - Mar 10, 2020
P2, N=100, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Lenabasum inhibits inflammasome activation, which could contribute to potential therapeutic efficacy in SSc and other autoimmune diseases. Trial completion date: Feb 2020 --> Dec 2020 | Trial primary completion date: Feb 2020 --> Dec 2020
- lenabasum (JBT-101) / Corbus Pharma, Kaken
Lenabasum clinical development update (Forum Hall) - Feb 21, 2020 - Abstract #SSWC2020SSWC_575;
- lenabasum (JBT-101) / Corbus Pharma, Kaken
[VIRTUAL] PATIENT AND PHYSICIAN OPINIONS OF CLINICAL BENEFIT AT 3 MONTHS IN A CLINICAL TRIAL CORRELATE WITH PATIENT-REPORTED OUTCOMES (PROS) (Poster Area) - Feb 21, 2020 - Abstract #SSWC2020SSWC_298;
Both the subject’s and physician’s opinion of clinical benefit early in treatment at 3 months correlated with the subject’s overall assessment of health related to SSc and change in skin symptoms. Larger and longer studies will help further elucidate what PROs reflect a SSc patient’s assessment of clinical benefit from treatment.
- lenabasum (JBT-101) / Corbus Pharma, Kaken
[VIRTUAL] HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX (HAQ-DI) AND PATIENT GLOBAL ASSESSMENT OF HEALTH (PTGA) CORRELATE WITH CHANGES IN PATIENT-REPORTED OUTCOMES (PROS) (Poster Area) - Feb 21, 2020 - Abstract #SSWC2020SSWC_297;
The correlations between changes in HAQ-DI and other patient-reported functioning and between change in PtGA and patient-reported symptoms were notable for their consistency over 2 years in this study. Both δ HAQ-DI and δ PtGA are included in the calculation of the ACR Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) score, suggesting this composite score may reflect both patient function and symptoms.
- ||| lenabasum (JBT-101) / Corbus Pharma, Kaken Pharma
Enrollment closed, Trial completion date, Trial primary completion date: Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis (clinicaltrials.gov) - Jan 13, 2020
P2, N=415, Active, not recruiting, Sponsor: Corbus Pharmaceuticals Inc.
Both δ HAQ-DI and δ PtGA are included in the calculation of the ACR Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) score, suggesting this composite score may reflect both patient function and symptoms. Recruiting --> Active, not recruiting | Trial completion date: Nov 2019 --> Aug 2020 | Trial primary completion date: Sep 2019 --> Jul 2020
- | bleomycin / Generic mfg., BMS, lenabasum (JBT-101) / Corbus Pharma, Kaken, EHP-101 / VivaCell Biotechnology, Emerald Health, Aphios
Biomarker, Journal: Cannabinoid derivatives acting as dual PPARγ/CB2 agonists as therapeutic agents for Systemic Sclerosis. (Pubmed Central) - Jan 10, 2020
Since both compounds are being tested in humans, we compared their activities in the bleomycin (BLM) SSc model...Finally, differences were found inplasmatic biomarker analysis; EHP-101, but not AjA, enhanced the expressionof some factors related to angiogenesisand vasculogenesis.Altogether the results indicate that dual PPARγ/CB2agonists qualify as a noveltherapeutic approach for the treatment of SSc and other fibrotic diseases. EHP-101 demonstratedunique mechanisms of action related to the pathophysiology of SSc that could bebeneficial inthetreatmentof this complex disease without current therapeutic options.
- || lenabasum (JBT-101) / Corbus Pharma, Kaken
$crbp KOL’s in rheumatology taking notice of promising Lenabasum OLE data in systemic sclerosis. Ph3 results in summer 2020 #acr19 (Twitter) - Dec 10, 2019
- || lenabasum (JBT-101) / Corbus Pharma, Kaken
you should also check out $crbp . Lenabasum drug in Ph3 for systemic sclerosis. No approved drugs with. $2bn+ peak revenue potential (Twitter) - Nov 19, 2019
- |||| lenabasum (JBT-101) / Corbus, Kaken
Clinical: Agreed Lenabasum Is drug to watch in systemic sclerosis . Best CRISS scores so far. CRISS superior to mRSS as it detects how patients feels and functions $crbp #acr19 (Twitter) - Nov 11, 2019
- ||| lenabasum (JBT-101) / Corbus, Kaken
Clinical: Lenabasum has an ACR CRISS of 95% at two years in Ph2 OLE and Ph3 data in summer 2020 . Way better safety profile than JAKs and best efficacy results so far #ACR19 $crbp (Twitter) - Nov 11, 2019
- |||| lenabasum (JBT-101) / Corbus, Kaken
Adverse events: Seems pretty poor compared with lenabasum. And even more considering the absence of serious side effects of CB2 agonists. (Twitter) - Nov 10, 2019
- | lenabasum (JBT-101) / Corbus Pharma, Kaken Pharma
Journal: Itch in dermatomyositis: the role of increased skin interleukin-31. (Pubmed Central) - Oct 30, 2019
EHP-101 demonstratedunique mechanisms of action related to the pathophysiology of SSc that could bebeneficial inthetreatmentof this complex disease without current therapeutic options. Increased skin IL-31 may play a role in DM-associated itch, and ongoing trials will evaluate the effects of systemic treatment on IL-31 and itch in DM.